Related Experiment Video
Updated: Jan 29, 2026

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
Published on: August 11, 2021
Targeting vesicular monoamine transporter Type 2 for noninvasive PET-based β-cell mass measurements
Antonella Maffei1, Paul E Harris2
1a Research Scientist, IGB - CNR: Institute of Genetics and Biophysics, Adriano Buzzati-Traverso, Naples, 80131, Italy. maffei@igb.cnr.it.
Abstract:
The common pathology in both Types 1 and 2 diabetes is insufficient β-cell mass to meet the metabolic needs of insulin production. The rising worldwide incidence of diabetes, combined with the lack of reliable endpoints of the body's true capacity to produce insulin, constitute a serious dilemma facing healthcare professionals and the pharmaceutical industry. Recent advances in imaging science and molecular imaging chemistry, as well as a broader understanding of basic islet biology, now allow the collection of quantitative information about β cells deep within the pancreas. The ability to noninvasively measure the mass of insulin-producing cells will most likely be of value towards characterizing new drugs and refining the diagnosis and treatment of this burdensome disease.
More Related Videos
Related Concept Videos
Mechanisms of Drug Absorption: Paracellular, Transcellular, and Vesicular Transport
However, most drugs use the transcellular route, traversing directly through the cell membranes via two mechanisms: passive and active transport. Passive...
Vesicular Tubular Clusters
With the help of motor proteins such...
Antihypertensive Drugs: Types of β-Blockers
Mass Analyzers: Common Types
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
Loss of Carboxy Group as CO2: Decarboxylation of β-Ketoacids

